Patients treated with IL-17 inhibitors had a pooled IR of 0.06 (95% CI, 0.02–0.18) melanoma events per 100 PYs, patients treated with IL-23 inhibitors had 0.10 (95% CI, 0.05–0.21) events per 100 PYs, and patients treated with JAK inhibitors had 0.09 (95% CI, 0.03–0.28) events per 100 PYs. Here, IL17A is linked to melanoma.